4-[2,3,6,7-四氢-3,7-二甲基-2,6-二氧代-1-(2-丙烯-1-基)-1H-嘌呤-8-基]-苯磺酸 | 149981-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 4-[2,3,6,7-四氢-3,7-二甲基-2,6-二氧代-1-(2-丙烯-1-基)-1H-嘌呤-8-基]-苯磺酸
• 英文名称: 1-allyl-3,7-dimethyl-8-(4-sulfophenyl)xanthine
• 英文别名: 1-allyl-3,7-dimethyl-8-p-sulfophenylxanthine；1-allyl-3,7-dimethyl-8-p-sulphophenyl-xanthine；1-Allyl-3,7-dimethyl-8-sulfophenylxanthine；4-(3,7-dimethyl-2,6-dioxo-1-prop-2-enylpurin-8-yl)benzenesulfonic acid
• CAS: 149981-25-9
• 化学式: C₁₆H₁₆N₄O₅S
• 分子量: 376.393
• InChiKey: CDMZOKMMANFJMU-UHFFFAOYSA-N

物化性质

• 熔点：
  >300°C
• 溶解度：
  在水中可溶

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-(3,7-二甲基-2,6-二氧代-2,3,6,7-四氢-1H-嘌呤-8-基)苯磺酰胺 在 sodium hydride 、 三氟乙酸 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 4-[2,3,6,7-四氢-3,7-二甲基-2,6-二氧代-1-(2-丙烯-1-基)-1H-嘌呤-8-基]-苯磺酸
  参考文献：
  名称：

  Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors

  摘要：

  An aryl p-(trifluoromethyl) substituent increases the affinity of 1,3-disubstituted 8-phenylxanthines at A2a-adenosine receptors, while having little effect on affinity at Al-adenosine receptors. In contrast, an aryl p-(trifluoromethyl) substituent has little effect on affinity of 3,7-disubstituted and 1,3,7-trisubstituted 8-phenylxanthines. An aryl p-sulfo substituent reduces affinity of all 8-phenylxanthines at A1-and A2a-adenosine receptors. An 8-(trifluoromethyl) substituent markedly reduces affinity of 1,3-dialkylxanthines at both A1- and A2a-adenosine receptors. In contrast, 8-(trifluoromethyl)caffeine retains affinity for A2a-adenosine receptors, but does lose affinity for A1-adenosine receptors. 8-Bromo-, 8-acryl-, and 8-pent-1-enylcaffeines are also selective for A2-adenosine receptors, while 8-cyclobutylcaffeine is nonselective. 8-[trans-2-(tert-butyloxycarbonyl)vinylcaffeine is 20-fold selective for Aza vs A1 receptors.

  DOI：

  10.1021/jm00070a007

文献信息

• Modulation of cellular DNA repair activity to intercept malignancy
  申请人：THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：US10188617B2

  公开（公告）日：2019-01-29

  Disclosed herein are methods for identifying compounds that enhance base excision repair, as well as compounds identified thereby and methods of using such compounds in the interception of malignancy, i.e. the prevention of progression of a disease from a state of susceptibility to active disease. Exemplified compounds are acetohexamide and related compounds, as well as benserazide and analogs thereof. Exemplified malignancies are those of human breast cells carrying mutations, in particular, SUM149 cells and HCC1937 cells, which cells carry BRCA1 mutations.

  本文公开了用于鉴定可增强碱基切除修复的化合物的方法，以及由此鉴定出的化合物和将此类化合物用于阻断恶性肿瘤的方法，即防止疾病从易感状态发展为活动性疾病的方法。示例化合物是乙酰己酰胺和相关化合物，以及苄丝肼及其类似物。示例性恶性肿瘤是携带突变的人类乳腺细胞，特别是携带 BRCA1 突变的 SUM149 细胞和 HCC1937 细胞。
• Materials and methods for binding nucleic acids to surfaces
  申请人：——

  公开号：US20020103350A1

  公开（公告）日：2002-08-01

  Surfaces containing high purity silica (silicon dioxide) exhibit high loading potential for nucleic acids. Formulations containing nucleic acids and materials which mask the electrostatic interactions between the nucleic acids and surfaces are disclosed. By masking the phosphate charges of the nucleic acids, undesired interactions may be minimized or eliminated, thereby allowing the covalent bonding of the nucleic acids to the surface to proceed. The use of such formulations additionally minimizes nonspecific binding of the nucleic acids to the surface. Examples of materials to be included in such formulations include cations, xanthines, hexoses, purines, arginine, lysine, polyarginine, polylysine, and quaternary ammonium salts.

  含有高纯度二氧化硅的表面具有很高的核酸负载潜力。 本研究公开了含有核酸的制剂和可掩盖核酸与表面之间静电相互作用的材料。通过掩盖核酸的磷酸电荷，可以最大限度地减少或消除不希望发生的相互作用，从而使核酸与表面的共价键结合得以进行。此外，使用此类制剂还能最大程度地减少核酸与表面的非特异性结合。可包括在此类制剂中的材料包括阳离子、黄嘌呤、己糖、嘌呤、精氨酸、赖氨酸、多精氨酸、多赖氨酸和季铵盐。
• Treatment of neurodegenerative disease
  申请人：——

  公开号：US20030060487A1

  公开（公告）日：2003-03-27

  In some aspects, the invention relates to treatments for peptide aggregation associated with disease states such as neurodegenerative disease, particularly physiology associated with Alzheimer's Disease, and non-neurodegenerative disease aggregation. Other aspects of the invention provide a variety of novel assays for screening candidate drugs. Yet other aspects of the present invention provide a series of compositions useful for treatment of peptide aggregation associated with disease states such as neurodegenerative disease, as determined from these assays. These compositions can be packaged in kits. Other aspects of the invention relate to the use of these compositions for the treatment and/or prevention of patients susceptible to or exhibiting symptoms characteristic of fibril formation or aberrant protein aggregation.

  在某些方面，本发明涉及与神经退行性疾病（尤其是与阿尔茨海默氏症相关的生理学疾病）等疾病状态有关的肽聚集以及非神经退行性疾病聚集的治疗方法。本发明的其他方面提供了多种用于筛选候选药物的新型检测方法。本发明的其他方面还提供了一系列用于治疗与神经退行性疾病等疾病状态相关的肽聚集的组合物，这些组合物是通过这些检测方法确定的。这些组合物可以包装成试剂盒。本发明的其他方面涉及使用这些组合物治疗和/或预防易患或表现出纤维形成或异常蛋白聚集特征症状的患者。
• TREATMENT OF NEURODEGENERATIVE DISEASE
  申请人：Minerva Biotechnologies Corporation

  公开号：EP1328261A2

  公开（公告）日：2003-07-23
• MODULATION OF CELLULAR DNA REPAIR ACTIVITY TO INTERCEPT MALIGNANCY
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：EP2968371A2

  公开（公告）日：2016-01-20